Plain-English translation of NCT04689347 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of four chemotherapy drugs—5-fluorouracil, , , and —plus a targeted drug called for people with advanced colorectal cancer whose tumors have a specific genetic marker called MGMT methylation. The goal is to see if this stronger combination works better than standard treatments. The medication is given through an intravenous line (IV) every two weeks, along with pills you take for five days every four weeks.
Standard chemotherapy treatments help some patients, but many don't respond well or lose the ability to continue treatment due to side effects. Researchers believe that giving multiple strong chemotherapy drugs upfront—rather than one at a time—might overcome drug resistance and help more patients, especially those whose tumors have the MGMT methylation marker.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous chemotherapy infusions every two weeks, combined with daily pills for five days every four weeks. The trial has an initial intensive phase of four 28-day cycles (about 4 months), followed by a maintenance phase if your cancer is responding. You'll have regular blood tests and imaging scans to monitor how well the treatment is working and to watch for side effects. The study takes place at the National Cancer Institute in Milan, Italy.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Italy